# Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects

> **NCT07169240** · PHASE1 · COMPLETED · sponsor: **ScinnoHub Pharmaceutical Co., Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Healthy Subjects (HS)

## Interventions

- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** BT-114143
- **DRUG:** 0.9% Sodium Chloride Injection as Placebo

## Key facts

- **NCT ID:** NCT07169240
- **Lead sponsor:** ScinnoHub Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-06
- **Primary completion:** 2024-04-17
- **Final completion:** 2025-08-02
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169240, "Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07169240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*